• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

术前中性粒细胞与淋巴细胞比值对非肌肉浸润性膀胱癌组织学亚型的预后价值。

Prognostic value of preoperative neutrophil-to-lymphocyte ratio in histological variants of non-muscle-invasive bladder cancer.

机构信息

Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China.

出版信息

Investig Clin Urol. 2021 Nov;62(6):641-649. doi: 10.4111/icu.20210278.

DOI:10.4111/icu.20210278
PMID:34729964
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8566785/
Abstract

PURPOSE

Many studies identified that the preoperative neutrophil-to-lymphocyte ratio (PNLR) was associated with patient prognosis in non-muscle-invasive bladder cancer (NMIBC). We hypothesized that PNLR could be prognostic in patients with histological variants of NMIBC (VH-NMIBC).

MATERIALS AND METHODS

This retrospective study included patients with VH-NMIBC admitted at our center between January 2009 and May 2019. The best cut-off value of NLR was measured by the receiver operating characteristic curve and Youden index. The Kaplan-Meier method and Cox proportional hazard regression models were employed to evaluate the association between PNLR and disease prognosis, including recurrence-free survival (RFS), progression-free survival (PFS), cancer-specific survival (CSS), and overall survival (OS).

RESULTS

A total of 243 patients with VH-NMIBC were enrolled in our study. According to the Kaplan-Meier method results, patients with PNLR ≥2.2 were associated with poor RFS (p<0.001), PFS (p<0.001), CSS (p<0.001), and OS (p<0.001). Multivariable analyses indicated that PNLR ≥ 2.2 was an independent prognostic factor of RFS (hazard ratio [HR], 2.11; 95% confidence interval [CI, 1.57-1.83; p<0.001), PFS (HR, 2.34; 95% CI, 1.70-3.21; p<0.001), CCS (HR, 2.87; 95% CI, 1.96-4.18; p< 0.001), and OS (HR, 2.83; 95% CI, 1.96-4.07; p<0.001).

CONCLUSIONS

This study identified that PNLR ≥2.2 was usually associated with a poor prognosis for patients with VH-NMIBC.

摘要

目的

许多研究表明,术前中性粒细胞与淋巴细胞比值(PNLR)与非肌层浸润性膀胱癌(NMIBC)患者的预后相关。我们假设 PNLR 可以预测组织学变异型 NMIBC(VH-NMIBC)患者的预后。

材料和方法

本回顾性研究纳入了 2009 年 1 月至 2019 年 5 月期间在我院就诊的 VH-NMIBC 患者。通过接收者操作特征曲线和 Youden 指数来测量 NLR 的最佳截断值。采用 Kaplan-Meier 法和 Cox 比例风险回归模型评估 PNLR 与疾病预后(包括无复发生存(RFS)、无进展生存(PFS)、癌症特异性生存(CSS)和总生存(OS))之间的关系。

结果

共纳入 243 例 VH-NMIBC 患者。根据 Kaplan-Meier 法的结果,PNLR≥2.2 的患者与较差的 RFS(p<0.001)、PFS(p<0.001)、CSS(p<0.001)和 OS(p<0.001)相关。多变量分析表明,PNLR≥2.2 是 RFS(危险比 [HR],2.11;95%置信区间 [CI],1.57-1.83;p<0.001)、PFS(HR,2.34;95% CI,1.70-3.21;p<0.001)、CSS(HR,2.87;95% CI,1.96-4.18;p<0.001)和 OS(HR,2.83;95% CI,1.96-4.07;p<0.001)的独立预后因素。

结论

本研究表明,PNLR≥2.2 通常与 VH-NMIBC 患者的不良预后相关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1910/8566785/a616d5639d09/icu-62-641-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1910/8566785/cbfe488fec5b/icu-62-641-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1910/8566785/e75cd43f2aad/icu-62-641-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1910/8566785/a616d5639d09/icu-62-641-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1910/8566785/cbfe488fec5b/icu-62-641-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1910/8566785/e75cd43f2aad/icu-62-641-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1910/8566785/a616d5639d09/icu-62-641-g003.jpg

相似文献

1
Prognostic value of preoperative neutrophil-to-lymphocyte ratio in histological variants of non-muscle-invasive bladder cancer.术前中性粒细胞与淋巴细胞比值对非肌肉浸润性膀胱癌组织学亚型的预后价值。
Investig Clin Urol. 2021 Nov;62(6):641-649. doi: 10.4111/icu.20210278.
2
Preoperative neutrophil-lymphocyte ratio can significantly predict mortality outcomes in patients with non-muscle invasive bladder cancer undergoing transurethral resection of bladder tumor.术前中性粒细胞与淋巴细胞比值可显著预测接受经尿道膀胱肿瘤切除术的非肌层浸润性膀胱癌患者的死亡率。
Oncotarget. 2017 Feb 21;8(8):12891-12901. doi: 10.18632/oncotarget.14179.
3
Validation of Neutrophil-to-lymphocyte Ratio in a Multi-institutional Cohort of Patients With T1G3 Non-muscle-invasive Bladder Cancer.多机构 T1G3 非肌层浸润性膀胱癌患者队列中中性粒细胞与淋巴细胞比值的验证。
Clin Genitourin Cancer. 2018 Dec;16(6):445-452. doi: 10.1016/j.clgc.2018.07.003. Epub 2018 Jul 6.
4
The prognostic value of routine preoperative blood parameters in muscle-invasive bladder cancer.常规术前血液参数在肌层浸润性膀胱癌中的预后价值。
BMC Urol. 2020 Mar 19;20(1):31. doi: 10.1186/s12894-020-00602-9.
5
Pre-treatment neutrophil-to-lymphocyte ratio as predictor of adverse outcomes in patients undergoing radical cystectomy for urothelial carcinoma of the bladder.术前中性粒细胞与淋巴细胞比值可预测行根治性膀胱切除术的膀胱癌患者的不良结局。
Br J Cancer. 2014 Jul 29;111(3):444-51. doi: 10.1038/bjc.2014.305. Epub 2014 Jun 10.
6
Prognostic Value of the Neutrophil-to-Lymphocyte Ratio in Nonmuscle-Invasive Bladder Cancer Treated with GreenLight Laser Vaporization.绿光激光汽化术治疗非肌层浸润性膀胱癌中中性粒细胞与淋巴细胞比值的预后价值
Photobiomodul Photomed Laser Surg. 2019 May;37(5):312-317. doi: 10.1089/photob.2018.4592. Epub 2019 Apr 11.
7
Preoperative neutrophil to lymphocyte ratio improves recurrence prediction of non-muscle invasive bladder cancer.术前中性粒细胞与淋巴细胞比值可改善非肌层浸润性膀胱癌的复发预测。
BMC Urol. 2018 Oct 22;18(1):90. doi: 10.1186/s12894-018-0404-x.
8
Prognostic value of modified Glasgow Prognostic Score in non-muscle-invasive bladder cancer.改良格拉斯哥预后评分在非肌层浸润性膀胱癌中的预后价值。
Urol Oncol. 2019 Mar;37(3):179.e19-179.e28. doi: 10.1016/j.urolonc.2018.11.005. Epub 2018 Dec 21.
9
The predictive value of the ratio of the product of neutrophils and hemoglobin to lymphocytes in non-muscular invasive bladder cancer patients with postoperative recurrence.中性粒细胞与血红蛋白乘积与淋巴细胞比值在非肌层浸润性膀胱癌术后复发患者中的预测价值
J Clin Lab Anal. 2021 Aug;35(8):e23883. doi: 10.1002/jcla.23883. Epub 2021 Jun 29.
10
Neutrophil-to-lymphocyte ratio predicts progression and recurrence of non-muscle-invasive bladder cancer.中性粒细胞与淋巴细胞比值可预测非肌层浸润性膀胱癌的进展和复发。
Urol Oncol. 2015 Feb;33(2):67.e1-7. doi: 10.1016/j.urolonc.2014.06.010. Epub 2014 Jul 21.

引用本文的文献

1
Evaluation of Cytokine Profile in Canine Malignant Oral Melanoma.犬恶性口腔黑色素瘤细胞因子谱的评估
Vet Sci. 2025 Jun 30;12(7):627. doi: 10.3390/vetsci12070627.
2
Microbiota and urinary tumor immunity: Mechanisms, therapeutic implications, and future perspectives.微生物群与泌尿系统肿瘤免疫:机制、治疗意义及未来展望
Chin J Cancer Res. 2024 Dec 30;36(6):596-615. doi: 10.21147/j.issn.1000-9604.2024.06.03.
3
State of the art of adjuvant immunotherapy in urothelial cancer: New developments and upcoming changes.尿路上皮癌辅助免疫治疗的现状:新进展与即将到来的变化

本文引用的文献

1
Accuracy of Transurethral Resection of the Bladder in Detecting Variant Histology of Bladder Cancer Compared with Radical Cystectomy.经尿道膀胱肿瘤切除术与根治性膀胱切除术检测膀胱癌变异组织学的准确性比较。
Eur Urol Focus. 2022 Mar;8(2):457-464. doi: 10.1016/j.euf.2021.04.005. Epub 2021 Apr 16.
2
Systemic combining inflammatory score (SCIS): a new score for prediction of oncologic outcomes in patients with high-risk non-muscle-invasive urothelial bladder cancer.全身综合炎症评分(SCIS):一种预测高危非肌层浸润性尿路上皮膀胱癌患者肿瘤学结局的新评分。
Transl Androl Urol. 2021 Feb;10(2):626-635. doi: 10.21037/tau-20-1272.
3
Hum Vaccin Immunother. 2025 Dec;21(1):2440165. doi: 10.1080/21645515.2024.2440165. Epub 2024 Dec 19.
4
A multimodal deep-learning model based on multichannel CT radiomics for predicting pathological grade of bladder cancer.一种基于多通道CT影像组学的多模态深度学习模型用于预测膀胱癌的病理分级。
Abdom Radiol (NY). 2024 Dec 18. doi: 10.1007/s00261-024-04748-0.
5
Role of repeat transurethral resection in no-muscle-invasive bladder tumour: an umbrella review.重复经尿道切除术在非肌层浸润性膀胱肿瘤中的作用:一项伞状综述
Ther Adv Med Oncol. 2024 Nov 16;16:17588359241298470. doi: 10.1177/17588359241298470. eCollection 2024.
6
GREM1 may be a biological indicator and potential target of bladder cancer.GREM1 可能是膀胱癌的生物学标志物和潜在靶点。
Sci Rep. 2024 Oct 7;14(1):23280. doi: 10.1038/s41598-024-73655-7.
7
Efficiency of transurethral en-bloc resection vs. conventional transurethral resection for non-muscle-invasive bladder cancer: An umbrella review.经尿道整块切除术与传统经尿道切除术治疗非肌层浸润性膀胱癌的疗效比较:一项伞状综述。
Cancer Med. 2024 Jun;13(11):e7323. doi: 10.1002/cam4.7323.
8
Efficiency of bladder-sparing strategies for bladder cancer: an umbrella review.膀胱癌保留膀胱策略的有效性:一项系统评价。
Ther Adv Med Oncol. 2024 May 10;16:17588359241249068. doi: 10.1177/17588359241249068. eCollection 2024.
9
An endothelial-related prognostic index for bladder cancer patients.一种用于膀胱癌患者的内皮相关预后指数。
Discov Oncol. 2024 Apr 25;15(1):128. doi: 10.1007/s12672-024-00992-4.
10
Revolutionizing Treatment: Breakthrough Approaches for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer.变革性治疗:卡介苗无反应性非肌肉浸润性膀胱癌的突破性治疗方法
Cancers (Basel). 2024 Mar 30;16(7):1366. doi: 10.3390/cancers16071366.
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.
《全球癌症统计数据 2020:全球 185 个国家和地区 36 种癌症的发病率和死亡率估计》。
CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4.
4
Bladder Cancer: A Review.膀胱癌:综述。
JAMA. 2020 Nov 17;324(19):1980-1991. doi: 10.1001/jama.2020.17598.
5
Clinical Characteristics and Prognosis of Rare Histological Variants of Bladder Cancer: A Single-Center Retrospective Study from China.膀胱癌罕见组织学变体的临床特征与预后:一项来自中国的单中心回顾性研究
Cancer Manag Res. 2020 Oct 7;12:9635-9641. doi: 10.2147/CMAR.S269065. eCollection 2020.
6
The multifaceted immune regulation of bladder cancer.膀胱癌的多方面免疫调控。
Nat Rev Urol. 2019 Oct;16(10):613-630. doi: 10.1038/s41585-019-0226-y. Epub 2019 Sep 9.
7
Elevated Neutrophil to Lymphocyte Ratio Predicts Poor Prognosis in Non-muscle Invasive Bladder Cancer Patients: Initial Intravesical Bacillus Calmette-Guerin Treatment After Transurethral Resection of Bladder Tumor Setting.中性粒细胞与淋巴细胞比值升高预示非肌层浸润性膀胱癌患者预后不良:经尿道膀胱肿瘤切除术后初始膀胱内卡介苗治疗情况
Front Oncol. 2019 Jan 17;8:642. doi: 10.3389/fonc.2018.00642. eCollection 2018.
8
Predictors of Residual T1 High Grade on Re-Transurethral Resection in a Large Multi-Institutional Cohort of Patients with Primary T1 High-Grade/Grade 3 Bladder Cancer.在一个大型多机构原发性T1高级别/3级膀胱癌患者队列中,再次经尿道切除术后残余T1高级别病变的预测因素。
J Cancer. 2018 Oct 20;9(22):4250-4254. doi: 10.7150/jca.26129. eCollection 2018.
9
Optimal body mass index cut-point for predicting recurrence-free survival in patients with non-muscle-invasive urothelial carcinoma of bladder.预测非肌层浸润性膀胱尿路上皮癌患者无复发生存的最佳体重指数切点
Oncol Lett. 2018 Sep;16(3):4049-4056. doi: 10.3892/ol.2018.9068. Epub 2018 Jul 4.
10
Validation of Neutrophil-to-lymphocyte Ratio in a Multi-institutional Cohort of Patients With T1G3 Non-muscle-invasive Bladder Cancer.多机构 T1G3 非肌层浸润性膀胱癌患者队列中中性粒细胞与淋巴细胞比值的验证。
Clin Genitourin Cancer. 2018 Dec;16(6):445-452. doi: 10.1016/j.clgc.2018.07.003. Epub 2018 Jul 6.